Black Diamond Therapeutics (BDTX)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from BDTX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Black Diamond Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $70M |
| Net income | -$126M | -$91M | -$82M | -$70M | $22M |
| Free cash flow | -$103M | -$85M | -$67M | -$62M | — |
| EPS (diluted) | -$3.47 | -$2.52 | -$1.88 | -$1.27 | $0.39 |
| Operating margin | — | — | — | — | 17.9% |
Superinvestors who own BDTX
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Black Diamond Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when BDTX trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Black Diamond Therapeutics insiders buying the stock?
No open-market insider purchases of BDTX in the last 12 months, according to SEC Form 4 filings.
Companies like Black Diamond Therapeutics
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.